Benchmark Antibodies Partners with Zeta Corporation to Bring IVD-Grade Antibodies to Research Laboratories
We’re excited to announce a new partnership between Benchmark Antibodies and Zeta Corporation, a recognized leader in the development of precision recombinant antibodies for immunohistochemistry (IHC). Through this collaboration, Benchmark is now offering Zeta’s extensive portfolio of high-performance IVD antibodies—specifically developed for clinical diagnostics—for research use only (RUO) applications.
Why Zeta Antibodies for Research?
Zeta’s antibodies are developed under stringent ISO 13485:2016 quality standards and FDA-registered manufacturing processes, originally intended for in vitro diagnostic (IVD) use in pathology labs. These same qualities offer clear advantages for researchers:
- Exceptional consistency: Each antibody is manufactured under standardized conditions for batch-to-batch reproducibility, reducing variability in your experiments.
- High specificity and sensitivity: Zeta’s antibodies—both their MonoMAb™ mouse monoclonals and RAbMono™ rabbit monoclonals—are engineered using cutting-edge protein chip screening and recombinant sequencing to ensure the highest target specificity.
- Optimized for FFPE tissue: These antibodies are extensively validated on formalin-fixed, paraffin-embedded (FFPE) tissue sections, making them ideal for translational and preclinical studies.
- Made in the USA: Domestic manufacturing ensures stable and responsive supply chains.
- Affordable: We offer these top-tier antibodies at competitive prices—providing unmatched price, performance, and consistency in one package.
About Zeta Corporation
With a catalog of over 400 tumor- and tissue-specific recombinant antibodies, Zeta is a global force in IHC innovation. Their antibodies are trusted by pathologists worldwide for reliable results across manual and automated platforms. Zeta’s expertise spans more than 75 years of collective experience in antibody development, and each product is validated for robust performance in differential tumor diagnosis.
